VAMP1
Basic information
Region (hg38): 12:6462237-6470677
Previous symbols: [ "SYB1" ]
Links
Phenotypes
GenCC
Source:
- myasthenic syndrome, congenital, 25, presynaptic (Strong), mode of inheritance: AR
- myasthenic syndrome, congenital, 25, presynaptic (Strong), mode of inheritance: AR
- presynaptic congenital myasthenic syndrome (Supportive), mode of inheritance: AD
- spastic ataxia 1 (Supportive), mode of inheritance: AD
- myasthenic syndrome, congenital, 25, presynaptic (Strong), mode of inheritance: AR
- spastic ataxia 1 (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Myasthenic syndrome, congenital, 25, presynaptic | AR | Musculoskeletal; Neurologic | The condition can involve neonatal hypotonia and generalized muscle weakness, and medicial management (with pyridostigmine) has been described as beneficial | Musculoskeletal; Neurologic | 11774073; 22958904; 28168212; 28253535; 28600779 |
ClinVar
This is a list of variants' phenotypes submitted to
- Spastic_paraplegia (88 variants)
- not_provided (22 variants)
- Myasthenic_syndrome,_congenital,_25,_presynaptic (9 variants)
- Inborn_genetic_diseases (5 variants)
- Spastic_ataxia_1 (4 variants)
- VAMP1-related_disorder (2 variants)
- Houge-Janssens_syndrome_2 (1 variants)
- Congenital_myasthenic_syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the VAMP1 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000014231.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 14 | 15 | ||||
| missense | 34 | 34 | ||||
| nonsense | 3 | |||||
| start loss | 0 | |||||
| frameshift | 9 | |||||
| splice donor/acceptor (+/-2bp) | 6 | |||||
| Total | 5 | 8 | 40 | 14 | 0 |
Highest pathogenic variant AF is 0.000015489852
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| VAMP1 | protein_coding | protein_coding | ENST00000396308 | 5 | 8751 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.00394 | 0.867 | 125737 | 0 | 11 | 125748 | 0.0000437 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 1.23 | 38 | 66.3 | 0.573 | 0.00000332 | 764 |
| Missense in Polyphen | 10 | 16.869 | 0.5928 | 222 | ||
| Synonymous | 0.471 | 20 | 22.9 | 0.875 | 0.00000112 | 233 |
| Loss of Function | 1.28 | 5 | 9.18 | 0.545 | 5.76e-7 | 87 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000578 | 0.0000578 |
| Ashkenazi Jewish | 0.0000992 | 0.0000992 |
| East Asian | 0.000109 | 0.000109 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000440 | 0.0000439 |
| Middle Eastern | 0.000109 | 0.000109 |
| South Asian | 0.0000327 | 0.0000327 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the targeting and/or fusion of transport vesicles to their target membrane.;
- Disease
- DISEASE: Spastic ataxia 1, autosomal dominant (SPAX1) [MIM:108600]: An autosomal dominant form of spastic ataxia, a progressive neurodegenerative disorder characterized by lower-limb spasticity and generalized ataxia with dysarthria, impaired ocular movements, and gait disturbance. {ECO:0000269|PubMed:22958904}. Note=The disease is caused by mutations affecting the gene represented in this entry. A mutation affecting a critical donor site for the splicing of VAMP1 isoforms leads to the loss of neuron-specific isoform 1 and subsequently results in haploinsufficiency (PubMed:22958904). Therefore, there would be less neurotransmitter exocytosis in specific regions of the brain, causing the symptoms of SPAX1. {ECO:0000303|PubMed:22958904}.;
- Pathway
- SNARE interactions in vesicular transport - Homo sapiens (human);Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics;Disease;Toxicity of botulinum toxin type D (BoNT/D);Toxicity of botulinum toxin type F (BoNT/F);Uptake and actions of bacterial toxins;Toxicity of botulinum toxin type G (BoNT/G);Neurotoxicity of clostridium toxins;Infectious disease
(Consensus)
Recessive Scores
- pRec
- 0.137
Intolerance Scores
- loftool
- rvis_EVS
- 0.24
- rvis_percentile_EVS
- 68.72
Haploinsufficiency Scores
- pHI
- 0.174
- hipred
- Y
- hipred_score
- 0.514
- ghis
- 0.552
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.815
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Low | Medium |
| Primary Immunodeficiency | Medium | Low | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Vamp1
- Phenotype
- growth/size/body region phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- synaptic vesicle priming;regulation of synaptic vesicle fusion to presynaptic active zone membrane;SNARE complex assembly
- Cellular component
- mitochondrial outer membrane;cytosol;integral component of plasma membrane;cell surface;cell junction;integral component of synaptic vesicle membrane;synaptic vesicle membrane;neuromuscular junction;azurophil granule membrane;specific granule membrane;neuron projection;tertiary granule membrane;glutamatergic synapse
- Molecular function
- protein binding